Oncology Where old pathways to innovative cancer care fall short, a n... Ignoring half the people in the world cannot be good for business.
News J&J says two drugs are better than one in pretreated myeloma Combining Johnson & Johnson's multiple myeloma therapies Talvey and Tecvayli shows promise in a hard-to-treat form of multiple myeloma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
